Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Medicinal Cannabis for Alzheimer's Disease

Medicinal Cannabis for Alzheimer's Disease
View Sample PDF
Author(s): Genevieve Z. Steiner-Lim (Western Sydney University, Australia), Madilyn Coles (Western Sydney University, Australia), Kayla Jaye (Western Sydney University, Australia), Najwa-Joelle Metri (Western Sydney University, Australia), Ali S. Butt (Western Sydney University, Australia), Katerina Christofides (Western Sydney University, Australia), Jackson McPartland (Western Sydney University, Australia), Zainab Al-Modhefer (Western Sydney University, Australia), Diana Karamacoska (Western Sydney University, Australia), Ethan Russo (University of Washington, USA)and Tim Karl (Western Sydney University, Australia)
Copyright: 2023
Pages: 47
Source title: Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
Source Author(s)/Editor(s): Rana R. Zeine (Kean University, USA)and Brian W. Teasdale (Kean University, USA)
DOI: 10.4018/978-1-6684-5652-1.ch001


View Medicinal Cannabis for Alzheimer's Disease on the publisher's website for pricing and purchasing information.


Alzheimer's disease (AD) is the most common form of dementia, and currently there is no cure. New therapeutic strategies that have the potential to address the complex pathophysiology of AD are urgently required; medicinal cannabis offers this possibility. Several potential leads can be extracted from Cannabis sativa (cannabis) that can target AD pathophysiology and alleviate symptoms, making it a prime candidate for AD drug discovery research. To date, most cannabis and AD research has focused on the major cannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), paying little attention to other plant constituents with therapeutic properties for AD. This chapter will highlight emerging evidence on the therapeutic potential of medicinal cannabis going beyond CBD and THC to discuss cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabinoid acids, and other cannabinoid homologs, terpenes, and flavonoids that may have relevance to AD therapy. Further, the entourage effect, clinical implications, and directions for future research will be discussed.

Related Content

Genevieve Z. Steiner-Lim, Madilyn Coles, Kayla Jaye, Najwa-Joelle Metri, Ali S. Butt, Katerina Christofides, Jackson McPartland, Zainab Al-Modhefer, Diana Karamacoska, Ethan Russo, Tim Karl. © 2023. 47 pages.
Mohd Kashif, Mohammad Waseem, Poornima D. Vijendra, Ashok Kumar Pandurangan. © 2023. 28 pages.
Courtney R. Acker, Rana R. Zeine. © 2023. 27 pages.
Mahesh Pattabhiramaiah, Shanthala Mallikarjunaiah. © 2023. 16 pages.
Dhairavi Shah, Dhaara Shah, Yara Mohamed, Danna Rosas, Alyssa Moffitt, Theresa Hearn Haynes, Francis Cortes, Taunjah Bell Neasman, Phani kumar Kathari, Ana Villagran, Rana R. Zeine. © 2023. 28 pages.
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Aneesa Zafar, Shahid Bashir. © 2023. 23 pages.
Akila Muthuramalingam, Ashok Kumar Pandurangan, Subhamoy Banerjee. © 2023. 17 pages.
Body Bottom